UK finds Roche bladder cancer drug too costly for routine use

LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.